Lifting the veil on amyloid drug design
High resolution structures and computational methods have been used to identify compounds that prevent amyloid fibrils associated with Alzheimer’s disease from dissociating into toxic species.
Main Authors: | Kathryn E Tiller, Peter M Tessier |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2013-07-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/01089 |
Similar Items
-
Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid beta
by: Lin Jiang, et al.
Published: (2013-07-01) -
A Biomimetic Multiparametric Assay to Characterise Anti-Amyloid Drugs
by: Willy Smeralda, et al.
Published: (2023-11-01) -
Aryloxypropanolamine targets amyloid aggregates and reverses Alzheimer-like phenotypes in Alzheimer mouse models
by: Hee Yang Lee, et al.
Published: (2022-11-01) -
Biflavonoid-Induced Disruption of Hydrogen Bonds Leads to Amyloid-β Disaggregation
by: Peter K. Windsor, et al.
Published: (2021-03-01) -
Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets
by: Zdeněk Fišar
Published: (2022-11-01)